Statins and Regression of Coronary Atherosclerosis

High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus

“…These findings suggest that statin benefits are derived from both reductions in atherogenic lipoprotein levels and increases in antiatherogenic lipoproteins, although it remains to be determined if this translates to significant reductions in CVD events (Nicholls, Tuzcu, Sipahi, et al, 2007). We have shown (by multiple regression analysis) that with 95% of CVD patients at LDL-C 100 mg/dl (2.6 mmol/l) in the structured care group of the GReek Atorvastatin And Coronary artery disease Evaluation (GREACE) the beneficial clinical outcome was associated with HDL-C increase, independently of LDL-C reduction (Athyros, Kakafika, Karagiannis, & Mikhailidis, 2007) and this may be related to improvement assessed by IVUS (Nicholls, Tuzcu, & Nissen, 2007). Thus, desirable levels of HDL-C may eventually need to be defined.…”

Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment

“…These findings suggest that statin benefits result from both the reduction in LDL-C levels and the increase in HDL-C. In the GREACE study, the statin-induced HDL-C increase was independently associated with lower CVD event rates [32, 98]. This suggests that the vascular risk reduction associated with HDL-C rise is significant even during aggressive LDL-C-lowering treatment (46% mean reduction in LDL-C levels) [32, 98].…”

“…In the GREACE study, the statin-induced HDL-C increase was independently associated with lower CVD event rates [32, 98]. This suggests that the vascular risk reduction associated with HDL-C rise is significant even during aggressive LDL-C-lowering treatment (46% mean reduction in LDL-C levels) [32, 98]. Interestingly, rosuvastatin increased HDL-C levels by increasing the cholesterol mass only in the larger HDL particles in a dose-dependent manner, suggesting a more effective reverse cholesterol transport [99].…”

High Density Lipoprotein Cholesterol and Statin Trials

“…For each mg/dl increment in baseline HDL-C, the hazard ratio for an event was 0.986 [95% confidence interval (CI) 0.979-0.994; p <0.001] [8]. Other studies showed that even small statininduced increases in HDL-C can translate into a clinical benefit [9,10]. Furthermore, the combination of statins with other lipid lowering agents [e.g.…”